secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0000950170-24-116856
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca reports 40% response rate in NRAS Q61X melanoma cohort from Phase 1b SEACRAFT-1 trial
--------------------------------------------------------------------------------

- 40% (4/10) response rate in efficacy-evaluable NRAS Q61X melanoma patients; 3 confirmed partial responses, 1 unconfirmed.
- 70% (7/10) of patients remained on treatment as of September 5, 2024 efficacy cutoff.
- Mandatory primary rash prophylaxis reduced skin toxicities and drug discontinuation rate vs. prior Novartis trials.
- Company expects SEACRAFT-2 Phase 3 randomized dose optimization data readout in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017024116856/0000950170-24-116856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017024116856/eras-20241024.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-116856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer